Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome [Phase 2]

View source ↗

Summary

Amgen conducted a Phase 2 trial to evaluate the efficacy and safety of VIB4920 in Sjögren's syndrome. The study is completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• VIB4920 (VIB4920)

Snippet

Sponsor: Amgen | Conditions: Sjögren's Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-04-30